Therapeutics/Vaccine Teams

治疗/疫苗团队

• 批准号: 8161305
• 负责人: CHARLES NICOLETTE
• 金额: $ 1506.74万
• 依托单位: ARGOS THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-30 至 2013-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8161305
• 关键词: Clinical Protocols; Clinical Trials; Clinical Trials Network; Collaborations; Contracts; Funding; HIV; HIV vaccine; Phase; Research Infrastructure; Resources; Testing; Vaccine Production; design; therapeutic vaccine

Each HIV Vaccine Team shall be required to perform the following activities and provide the following resources: 1. Develop a specific therapeutic HIV vaccine concept into a product capable of being tested in a clinical trial. 2. Provide for the production of vaccine products under Good Manufacturing Practices (GMP). 3. Provide the requisite infrastructure, facilities, and resources for performing all phases of the contract. 4. Design and implement one or more clinical protocols, independently or in collaboration with a DAIDS-funded HIV/AIDS clinical trials network,

应要求每个艾滋病毒疫苗小组开展以下活动并提供以下资源： 1.将特定的治疗性艾滋病毒疫苗概念发展成能够在临床试验中进行测试的产品。 2.规定按照良好生产规范（GMP）生产疫苗产品。 3.为履行合同的所有阶段提供必要的基础设施、设备和资源。 4.独立或与DAIDS资助的艾滋病毒/艾滋病临床试验网络合作，设计和实施一项或多项临床方案，